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Purpose: Varicella has a high incidence affecting the
vast majority of the population in France and can lead
to severe complications. Almost every individual
infected by varicella becomes susceptible to herpes
zoster later in life due to reactivation of the latent
virus. Zoster is characterized by pain that can be long-
lasting in some cases and has no satisfactory treat-
ment. Routine varicella vaccination can prevent
varicella. The vaccination strategy of replacing both
doses of measles, mumps, and rubella (MMR) with a
combined MMR and varicella (MMRV) vaccine is a
means of reaching high vaccination coverage for
varicella immunization. The objective of this analysis
was to assess the impact of routine varicella vacci-
nation, with MMRV in place of MMR, on the
incidence of varicella and zoster diseases in France
and to assess the impact of exogenous boosting of
zoster incidence, age shift in varicella cases, and other
possible indirect effects.
Methods: A dynamic transmission population-
based model was developed using epidemiological
data for France to determine the force of infection,
as well as an empirically derived contact matrix to
reduce assumptions underlying these key drivers
of dynamic models. Scenario analyses tested assump-
tions regarding exogenous boosting, vaccine waning,*Abbott Healthcare Products B.V., Weesp, the Netherlands.
†Littlewood Writing Solutions, Houten, the Netherlands.
816vaccination coverage, risk of complications, and con-
tact matrices.
Findings: The model provides a good estimate of
the incidence before varicella vaccination implemen-
tation in France. When routine varicella vaccination is
introduced with French current coverage levels, vari-
cella incidence is predicted to decrease by 57%, and
related complications are expected to decrease by
76% over time. After vaccination, it is observed that
exogenous boosting is the main driver of change in
zoster incidence. When exogenous boosting is as-
sumed, there is a temporary increase in zoster in-
cidence before it gradually decreases, whereas without
exogenous boosting, varicella vaccination leads to a
gradual decrease in zoster incidence. Changing vaccine
efﬁcacy waning levels and coverage assumptions are
still predicted to result in overall beneﬁts with varicella
vaccination.
Implications: In conclusion, the model predicted
that MMRV vaccination can signiﬁcantly reduce
varicella incidence. With suboptimal coverage, a
limited age shift of varicella cases is predicted to occur
post-vaccination with MMRV. However, it does not
result in an increase in the number of complications.0149-2918/$ - see front matter
& 2015 The Employers. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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INTRODUCTION
Both varicella and herpes zoster diseases are expres-
sions of the same pathogen—the varicella zoster virus
(VZV), which is highly contagious and transmitted by
inhalation of infectious particles or via person-to-
person contact.1,2 Varicella is a highly prevalent
disease worldwide, affecting most of the population,
typically young children. Besides substantial levels of
varicella-associated morbidity and mortality, there is
also an indirect burden on parents and caregivers.2
In 2010, 766,000 new cases of varicella were
estimated to occur in France.3 A seroprevalence
study estimated that 90% of children already had
VZV antibodies by 8 years of age,4 and a few studies
reported the median age of varicella infection to be
4 years.5,6 Additionally, it has been reported that
the risk of complications due to varicella is high in
infants, children, and young adults.7 In France, severe
varicella complications lead to an estimated 20 deaths
per year.8
Herpes zoster, which is characterized by a painful
rash, mainly affects older individuals 50 to 60 years of
age, and it appears that the risk of herpes zoster
increases with age.9 The VZV reactivates in this age
group, possibly due to decreasing cell-mediated im-
munity that is associated with aging.1 A sentinel survey
in France estimated an annual incidence of 3.2 cases of
herpes zoster (95% CI, 3.03.4) per 1000 inhabitants,
18.4% of whom reported chronic pain.10 This chronic
pain after zoster is known as postherpetic neuralgia,
which is suggested to last for long periods of time and
is reported to have a detrimental impact on the quality
of life.11,12 Zoster and postherpetic neuralgia are
difﬁcult to manage and treat; however, they can also
be self-remitting.12
Effective prevention of varicella disease exists in the
form of a vaccine against varicella, which is also
suggested to result in a decrease in zoster disease
incidence in vaccine recipients (attributed to a lower
reactivation rate with the vaccine strain of the vi-
rus).13,14 The World Health Organization recommends
routine varicella vaccination in countries where highApril 2015levels of coverage can be achieved and maintained.2
Thus, using the combined measles, mumps, rubella,
and varicella (MMRV) vaccine instead of the measles,
mumps, and rubella (MMR) vaccine, which is
presently used in routine immunization programs in
the majority of countries worldwide, is suggested to
be an efﬁcient strategy to provide routine varicella
vaccination at high levels of vaccination coverage.2
Varicella vaccination programs in Europe are aimed
at high-risk groups, and routine varicella vaccination is
not yet widely implemented, mainly due to concerns
about the possible indirect effects of routine vaccina-
tion and its budget requirements. Further evidence is
needed of the indirect effects of varicella vaccination
such as the impact of herd immunity on the age of
acquisition of varicella infection and the impact of the
exogenous boosting on zoster disease incidence. It is
widely suggested that the average age at which varicella
infection occurs could increase due to the herd im-
munity effect, and this could result in a high risk of
complications.2 Conversely, if exogenous boosting of
immunity exists, then zoster incidence could
temporarily increase after vaccination due to fewer
contacts with varicella cases.15,16 It was ﬁrst hypothe-
sized by Hope-Simpson17 in 1965 that re-exposure to a
wild-type VZV might boost immunity against the
reactivation of latent VZV and therefore would lower
the probability of developing zoster diseases. This
exogenous boosting hypothesis can imply that a
vaccine-induced reduction in circulating wild-type
VZV leads to a temporary increase in zoster inci-
dence.17–21 However, there is conﬂicting evidence of
the existence of such an exogenous boosting effect that
links an increase in the number of zoster cases and the
adoption of routine varicella vaccination.22 In a recent
publication by Brisson et al,23 the assumptions
regarding exogenous boosting effects from previous
models were updated to precise age-speciﬁc estimates
(ie, the 100% input [percentage of effective varicella
contacts that boost against zoster]) was now reduced to
a maximum of 75% for individuals younger than 50
years of age and as low as 32% for those older than 80
years of age.23
Under these circumstances, the beneﬁts of routine
varicella vaccination on varicella incidence and poten-
tially zoster incidence in vaccine recipients that would
result in long-term beneﬁts need to be weighed against
the hypothetical increase in varicella and zoster cases
due to indirect vaccination effects. The objective of this817
Clinical Therapeuticsage-speciﬁc, population-based dynamic model study was
to assess the impact of routine varicella vaccination on
the incidence of varicella and zoster diseases in France.
The model speciﬁcally evaluates any age shifts in varicella
incidence and the impact of exogenous boosting assump-
tions on the incidence of zoster disease.
METHODS
Model Description
After a review of the literature and varicella zoster
models, the dynamic models by Brisson et al13,23 and
Schuette and Hethcote24 were found to be the most
comprehensive because they included an age-speciﬁc
stratiﬁcation, zoster in the disease arm (exogenous
boosting), waning effects, and herd immunity.
A dynamic transmission model was developed using
ModelMaker® version 4.0 (Informer Technologies,
Inc.), using the same basic structure as the model by
Brisson et al,13,23 to reﬂect both varicella and zoster
diseases over a lifetime, to measure the impact of age-
speciﬁc exogenous boosting versus no exogenous
boosting, and to capture age-speciﬁc effects of herd
immunity. The model was age speciﬁc and had 66 age
groups (1-year wide age groups until 65 years of age,
then 65 years of age and older). The aging process wasNatural
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818partly discrete (aging and birth occurred once a year)
and partly continuous (death). The death rate of
individuals in the age group 65 years of age and older
was adjusted to ensure a constant population in the
model. In contrast to the original model of Brisson
et al,13 this model includes zoster infection in the
vaccination arm, an empirically derived contact
matrix, and a vaccination strategy with 2 doses of
MMRV instead of 1. This model also uses age-speciﬁc
exogenous boosting assumptions based on the recent
version of the Brisson et al23 model.
The model structure presented in Figure 1 shows the
varicella disease states as susceptible, latent or exposed,
infectious, and recovered and zoster disease states as
susceptible, infectious, and recovered. Decreasing
immunity with age causes recovered varicella patients
to become susceptible to zoster, and exogenous
boosting partially offsets this effect. The normal
disease progression (before vaccination) is shown in
black, and the postvaccination disease states are shown
in red (Figure 1).
French data are used where possible; for example,
the rate of VZV reactivation (ie, zoster developing)
was age dependent and estimated to match the
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M.J.N.M. Ouwens et al.become fully protected (varicella protected) or partially
protected (varicella susceptible) and primary vaccine
failures are shown to remain in the varicella susceptible
state. After 2 doses of MMRV, most partially protected
vaccine recipients become fully protected. Break-
through cases (varicella or zoster cases after vaccina-
tion) are assumed to be milder than naturally acquired
cases of varicella or zoster25 and that vaccination also
results in lower infection and reactivation rates. All
input parameters and vaccine assumptions including
the differential equations used in the model are
provided in Appendix A.Force of Infection
The force of infection (FOI) is estimated based on age-
speciﬁc French incidence data from INSERM26 (Table I).
It is assumed that on average 98% of individuals 65 years
of age and older will have had varicella and that the
proportion of susceptible individuals in each age group
decreases exponentially. Zoster cases, as in other models,
are assumed to have a negligible inﬂuence on the FOI
compared with varicella cases.Contact Matrix
A contact matrix provides information on contact
rates between individuals in the same age group and
different age groups. Empirically based contact matri-
ces for 8 European countries were recently published,27
and because no empirical French data are available, the
contact data from Italy were chosen as a proxy and
corrected for age group size.Table I. FOI by age group (applicable to
susceptible population).
Age Group (y) FOI*
0 to o1 0.0651
1–4 0.2407
5–9 0.2101
10–14 0.0672
15–24 0.0319
25–44 0.0288
45–64 0.0236
65þ 0.0079
FOI ¼ force of infection.
*Based on INSERM.26
April 2015The model uses a “who acquires infection from
whom” (WAIFW) matrix, which combines the contact
matrix, FOI, and the virulence of the VZV. The FOI
due to zoster cases is small compared with the FOI due
to varicella cases. Consequently, the WAIFW matrix is
estimated solely based on the FOI due to varicella
(Appendix B).
Vaccination Base Case Scenarios: French Current
Coverage and Optimal Coverage
A French current coverage scenario assumes the
coverage objectives of the Public Health Authorities
(ie, 90% and 80% coverage rates for the MMR
vaccine for dose 1 [at 12 months] and dose 2 [at 18
months], respectively).28 In this scenario, it is assumed
that up to 80% of MMR would gradually be replaced
by MMRV over a period of 3 years. The optimal
coverage scenario assesses the impact of improving the
French current coverage (ie, 95% [dose 1] and 90%
[dose 2]) with full replacement (100%) of MMR with
MMRV over a period of 3 years. The optimal coverage
scenario is evaluated because the uptake of a second
dose of MMRV is rapidly increasing, and the
vaccination coverage is lower in France compared
with other countries (Table II).
In both base case scenarios, a catch-up program for
children 10 years of age is implemented with vacci-
nation coverage levels of 50% and is assumed to last
for 8 years (ie, until the original vaccine recipients
reach the catch-up age eligibility). After target levels of
vaccination coverage are attained, it is assumed that
these levels of coverage are maintained over time with
no disruption in vaccine logistics and supply.
MMRV vaccine efﬁcacy data are obtained from clinical
trials; it is shown that 65% of individuals are fully
protected after the ﬁrst dose, and an additional 30%
move from partial to full protection after the second
dose.29 The proportion of primary vaccine failures
(corresponding to subjects with no seroconversion) is
assumed to be 5%.29 Based on observational data from
Israel, it is estimated that vaccine-induced immunity will
wane over time, with an average duration of 17 years after
1 dose and lifelong protection after 2 doses.14
Exogenous immunity boosting assumptions in the
base case are based on recent model assumptions,23
which, unlike previous models for France,30 assume an
age-speciﬁc exogenous boosting outcome; therefore,
based on this assumption, vaccination would still result
in a temporary increase in zoster cases among819
Table II. Base case and scenario analyses.
Description French Coverage Optimal Coverage
Base case analysis Vaccination coverage of MMR dose 1 and 2 Dose 1: 90%;
Dose 2: 80%
Dose 1: 95%;
Dose 2: 90%
Fraction of MMR replaced by MMRV, % 80 100
Time for replacement (MMR by MMRV), y 3 3
Catch-up program 50% in 10 year olds 50% in 10 year olds
Exogenous boosting Included Included
Contact matrix Empirical Empirical
Vaccine protection Post-dose 1: 17 y;
Post-dose 2: lifelong
protection
Post-dose 1: 17 y;
Post-dose 2: lifelong
protection
Immunity against zoster 10 y 10 y
Scenario analyses
No exogenous boosting Same as base case except exogenous boosting Excluded
Alternative contact matrices Same as base case except contact matrix Assortative and proportionate matrices
Vaccination coverage Same as base case except vaccination
coverage of dose 1 and 2
Coverage from 0 to 100%; same vaccination
coverage for doses 1 and 2
Waning vaccine efﬁcacy Same as base case except waning of
vaccine-induced protection
Post-dose 1: 10 y; Post-dose 2: 30 y
Duration of immunity against zoster Same as base case except the duration
of immunity against zoster
2–20 y of immunity against zoster after
varicella episode or contact with a varicella case
(exogenous boosting)
Risk of complications Same as base case except for complication rates Rates of varicella complications are set equal
for those vaccinated and those not
vaccinated
MMR ¼ measles, mumps, and rubella; MMRV ¼ measles, mumps, rubella, and varicella.
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M.J.N.M. Ouwens et al.nonvaccinated individuals. Similarly, if individuals
who are protected by varicella vaccination come into
contact with infectious varicella, this could boost the
immune response against VZV and result in lifelong
protection from varicella. The WAIFW matrix is based
on the empirically derived contact matrix from Mos-
song et al.27
Incidence results are presented for individuals div-
ided into 8 age groups (ages o1 year, 1–4 years, 5–9
years, 10–14 years, 15–24 years, 25–44 years, 45–64
years, and 65þ years), reﬂecting preschool and school-
children in France, the working population, and elderly
individuals. The preschool age group is subdivided into
nonvaccinated infants younger than 1 year of age and
potentially vaccinated 1 to 4 year olds.
Scenario Analyses
The main question was to assess whether there was
a shift in the peak age of varicella incidence after
vaccination and to evaluate the magnitude of increase
in zoster incidence arising from exogenous boosting
assumptions. Uncertainty surrounding key model pa-
rameters such as the contact matrix and the long-term
effect of vaccination due to assumptions about waning
vaccine efﬁcacy was tested in this scenario analysis.
An additional analysis was performed to test the
impact of a scenario without exogenous boosting (no
exogenous boosting) on the model results. This was
performed using 2 alternative contact matrices (propor-
tionate and assortative), commonly reported in the
literature to assess the extremes of contacts (alternative
contact matrices). A scenario analysis assessed the
vaccination coverage (vaccination coverage) threshold
at which an age shift occurs and the impact on
complications and breakthrough cases. Another sce-
nario assessed a shorter duration of vaccine-induced
protection by assuming waning of efﬁcacy (waning
vaccine efﬁcacy), which was 10 years with 1 dose and
30 years with 2 doses (instead of 17 years and lifelong
in the base case). In another scenario, waning of natural
immunity against zoster (ie, 10 years in the base case
was varied using 2 extreme values: 2 years and 20
years). Finally, we assessed the impact of varicella
vaccination on complications using varying coverage
rates as a separate scenario. In the base case, it is
assumed that breakthrough varicella cases are milder
and therefore lead to fewer complications compared
with natural varicella cases (10% relative risk). In a
more conservative scenario, the same risk ofApril 2015complication is applied to both breakthrough and
natural varicella cases (risk of complications) (Table II).RESULTS
Model Validation
The modeled age-speciﬁc incidence of varicella at
steady state before vaccination was a close match
compared with the observed incidence data for France
from INSERM26 (Appendix C).31 In France, the
incidences of varicella and zoster are 12 and 4 cases
per 1000 person-years, respectively.Base Case Analysis: Impact on Varicella
Age-Specific Incidence
Figure 2 shows the number of varicella cases per
thousand person-years for each age group during and
up to 80 years after vaccination. The start of vacci-
nation is assumed at year 0.
It is seen that MMRV vaccination is expected to
reduce the incidence of varicella in the population over
time. With routine varicella vaccination at French
current coverage levels, varicella incidence is predicted
to decrease by 57%. Of a total varicella incidence of 12
cases per 1000 person-years, 62.5% (7.5 cases per
1000 person-years) of cases were observed in children
1 to 4 years of age before MMRV vaccination. For the
base case French current coverage scenario, implemen-
tation of routine MMRV vaccination is expected to
result in an initial decrease, after which a temporary
increase in the varicella incidence in children 5 to 9
years of age (to a maximum of 5.4 per 1000 person-
years total population 4 years after vaccination; age-
speciﬁc incidence of 84 per 1000 person-years) and in
adolescents 10 to 14 years of age (to a maximum of 3.7
per 1000 person-years total population 11 years after
vaccination; age-speciﬁc incidence of 58 per 1000
person-years) is observed (Figure 2A). For the optimal
coverage scenario, the incidence in children 1 to 4 years
of age is projected to be reduced further than in the
French coverage scenario. In the 5- to 9-year age
group, this maximum incidence was higher, whereas
in the 10- to 14-year age group, the maximum
incidence was lower (Figure 2B). The transitory
behavior of the model in the ﬁrst 20 years after
vaccination can be attributed to variations in herd
immunity effects and to assumptions of homogeneous
contacts with vaccination occurring annually on the
ﬁrst day of the year.821
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Figure 2. Modeled varicella cases (per 1000 person-years of total population) by age group. A, French current
coverage; B, optimal coverage.
Clinical TherapeuticsMMRV vaccination is expected to result in an age
shift, from a mean age of 6 years without varicella
vaccination to a mean age of 20 years for the French
current coverage scenario and a mean age of 35 years
for the optimal coverage scenario. The age shift is
accompanied by an increase in varicella incidence of
0.97 to 1.60 per 1000 person-years for the French
current coverage in individuals 20 years of age and
older, but with a decrease in this age group from 0.97
to 0.49 per 1000 person-years in the optimal coverage
scenario. However, at equilibrium, in individuals 20
years of age and older, half of the varicella cases are
mild breakthrough cases in the French coverage sce-
nario and are less likely to lead to complications.
Across all age groups, varicella complications were
reduced by 76% and 98% for the base case French
coverage and optimal coverage scenarios, respectively.
For the optimal coverage scenario, varicella incidence is
expected to become negligible in all age groups (o0.2822cases per 1000 person-years of total population). The
impact on complications was further explored in the
scenario analyses.Scenario Analyses
No Exogenous Boosting: Impact on Zoster Incidence
(Base Case)
Vaccination is predicted to result in a decrease in the
number of varicella cases. However, given the assump-
tions about age-speciﬁc exogenous boosting, a tempo-
rary increase in the number of zoster cases is observed
(Figure 3). It has been hypothesized that varicella
vaccination results in a lower risk of zoster disease in
vaccine recipients and consequently a decrease in the
incidence of zoster is expected as vaccine recipients
reach the age at which zoster is more likely to occur.
Because the current coverage in France is lower than
the optimal coverage, the incidence of zoster disease at
80 years after vaccination is higher than that expectedVolume 37 Number 4
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M.J.N.M. Ouwens et al.for the optimal coverage scenario. On the other hand, a
temporary increase in the zoster disease incidence is
slightly smaller for the French current coverage.
In a scenario without exogenous boosting, the
incidence of zoster disease is predicted to gradually
decrease after the introduction of routine MMRV
vaccination due to the fact that an increasing propor-
tion of the population is vaccinated, and in these
individuals, the risk of zoster disease is assumed to be
lower. The base case scenario took the conservative
assumption that an age-speciﬁc proportion of people
would have exogenous immunity boosting (ie, 75% of
individuals younger than 50 years of age, 71% of
individuals 50–64 years of age, and 50% of those 65
years of age and older). Thus, the incidence of zoster
increases for a period of 16 years under the French
current vaccination coverage assumption and up to 14
years under the optimal coverage assumption and isApril 2015then predicted to decrease. The estimated incidence is
3.97 per 1000 person-years before vaccination. For the
French current coverage and optimal coverage scenar-
ios, 9 years after vaccination, the zoster incidence is
predicted to reach a maximum of 4.11 and 4.12 per
1000 person-years, respectively.Alternative Contact Matrices: Impact on Varicella
Incidence
The assortative matrix and the proportionate ma-
trix consider different assumptions about the contact
rates between individuals that would have an impact
on VZV transmission dynamics in the population.
Vaccination of infants is therefore known to have an
impact through herd immunity on individuals in the
other age groups resulting from the assumptions of
contact patterns in the population. In the assortative
matrix, contacts are mainly in the same age groups,
whereas in the proportionate matrix, contacts are
spread across different age groups. Therefore, the
assortative matrix assumptions will result in more
varicella cases because as herd immunity has a lesser
impact (protection only in individual age groups),
whereas the proportionate matrix assumptions will
result in fewer varicella cases because herd immunity
has a greater impact (protection across age groups).
The alternative contact matrix options can therefore
be seen as providing worst and best case scenarios,
respectively.
The model predicts a large decrease in the number
of varicella cases for both base case scenarios under
the assumption of using alternative contact matrix
options. However, for the French current coverage
scenario, the assortative contact matrix results in a
decrease from 12.7 to 5.4 cases per 1000 person-years,
whereas the proportionate matrix results in a further
decrease to 1.2 cases per 1000 person-years. For the
optimal coverage scenario, the assortative matrix
results (varicella incidence of 3.5 cases per 1000
person-years) in a smaller decrease than the propor-
tionate matrix (0.3 cases per 1000 person-years) 80
years after starting vaccination (Figure 4). The
scenario analyses using alternative contact matrix
options demonstrate that the assumptions about
contact patterns are the key drivers of the model
results. In all cases, varicella vaccination signiﬁcantly
reduces the incidence of varicella by 59% to 94% at
30 years for the French current coverage and 477%
for the optimal coverage scenario.823
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Clinical TherapeuticsVaccination Coverage: Impact on Age Distribution of
Varicella Cases
The change in varicella incidence and complications
as a function of the coverage rate in individuals at least
20 years of age is shown in Figure 5. Compared with
no vaccination, the maximum increase in varicella
cases in those 20 years of age and older reaches 5%
for vaccination coverage levels in the range of 30% to
40% (Figure 5A). At 65% vaccination coverage, the
predicted incidence in that age group is expected to
match the prevaccination incidence, and the incidence
is expected to decrease at higher levels of vaccination
coverage. Additionally, it is estimated that after
vaccination, some varicella cases are breakthrough
cases, and these are known to be milder than the
natural cases of varicella (Figure 5B). As a consequence,
the largest increase in terms of complications reaches
0.8% compared with no vaccination and is expected to
occur at a vaccination coverage of 20%. Across all age824groups, the incidence of complications decreases
proportionally with vaccination coverage (Figure 5A).Risk of Varicella Complications: Impact on
Complications and Breakthrough Cases
The incidence of complications was expected to
decrease because there were fewer cases of varicella
after vaccination, but also because of the assumption
that breakthrough cases result in fewer deaths and less
loss of quality of life. The change in the number of
complications follows the incidence pattern, with the
new expected rate of complications presented at 30
years after introduction of MMRV. Remarkably, theVolume 37 Number 4
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Figure 7. Varicella complications by age before
and 30 years after measles, mumps,
rubella, and varicella (MMRV) vaccine
introduction. A, French current cover-
age; B, optimal coverage.
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Figure 6. Base case: varicella complications by
type before and after measles, mumps,
rubella, and varicella (MMRV) vaccine
introduction. A, French current cover-
age; B, optimal coverage.
M.J.N.M. Ouwens et al.highest rate of complications 5 years after the start of
vaccination coincides with the peak in the varicella
incidence in the same year (Figure 6).
The pattern of complications by age group before
and after MMRV vaccine introduction is presented in
Figure 7. Varicella in the vaccinated group included
mostly breakthrough cases. Both base case scenarios
assume that breakthrough cases have 10% of the
complications seen with natural varicella cases. Figure 7
presents the rate of complications in a scenario in which
the risk of complications is assumed to be same (equal)
for both breakthrough and natural varicella cases. It is
seen that the rate of complications was greatly reduced in
the overall population after implementation of varicella
vaccination. A deﬁnite reduction in the incidence of
complications was observed in children younger thanApril 201510 years of age, and children 1 to 4 years of age would
beneﬁt the most from the reduction from 347 to 17 per
1,000,000 person-years with the French coverage. How-
ever, the incidence of complications (per 1,000,000
person-years) increased from 20 to 33 and from 4 to 5,
respectively, in the age groups 10 to 14 years and 15 to 19
years, respectively. The incidence of complications is also
reduced in adults 20 years of age and older from 84 to 67
per 1,000,000 person-years.
Although early observations indicate that most
breakthrough cases will not result in complications,
similar results were obtained when assuming that
breakthrough cases cause as many complications as
natural cases (see the equal scenario in Figure 7) except
that an increase from 84 to 87 per 1,000,000 person-
years is observed for adults 20 years and older. The
changes in the incidences of varicella and zoster
diseases will have an impact on the number of825
Clinical Therapeuticscomplications and deaths caused by VZV and con-
sequently on the health care and societal costs. The
epidemiological results are therefore used as a basis for
an economic evaluation of MMRV vaccination in
France, which is also being reported in parallel (Little-
wood et al).32Waning Vaccine Efficacy: Impact on Varicella and
Zoster Incidence
With a shorter duration of protection (ie, faster
waning of vaccine efﬁcacy), a large number of varicella
cases are predicted to occur (Figure 8). As exogenous
boosting is assumed, this slightly reduces the increase
in zoster incidence but results in more varicella cases in
the long term compared with both base case scenarios.
In the very long term scenario (ie, 80 years after
vaccination), zoster incidence is also expected to be
slightly higher than for both base case scenarios when
assuming a shorter duration of vaccine-induced
protection.Duration of Immunity against Herpes Zoster
(Parameter δ): Impact on Zoster Incidence
When varying the duration of immunity against
zoster, the prevaccination incidence of zoster was
reproduced with different values of δ and age-speciﬁc
reactivation rates ρ. The shorter waning period of 2
years resulted in virtually no increase in postvaccina-
tion zoster incidence. The longer waning period ofNo MMRV
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Figure 8. Varicella incidence with shorter waning durati
82620 years resulted in a period of 40 years with increased
zoster incidence; the maximum increase of 8% oc-
curred at 18 years after vaccine introduction.DISCUSSION
In this analysis, a dynamic model was used to assess the
impact of a 2-dose routine varicella vaccination pro-
gram on the incidence of varicella and zoster diseases
in France. The model results show that vaccination is
expected to reduce the overall incidence of varicella
and zoster diseases. Although MMRV vaccination is
predicted to result in a temporary increase in the
number of zoster cases, a limited shift in the average
age of varicella patients is observed with the French
coverage. Although a substantial proportion of cases in
older children are mild breakthrough cases, therefore,
the age shift does not result in an increase in the
number of complications. The use of an empirically
derived contact matrix reduces the need for assump-
tions about contact patterns, which is a key driver of
results. Age shifts in varicella cases may be encountered
if the French current coverage value does not increase
to the optimal coverage. The model predicted an
increase in varicella cases only in adolescents 10 to
14 years of age in whom the incidence of complications
increased from 20 to 32 per million population.
However, across all age groups, varicella complications
were reduced by 76% and 98% for the base case
French coverage and optimal coverage scenarios,No MMRV
Base case
Shorter 
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No MMRV
Base case
Shorter 
protection
Zoster cases French current coverage
5000
4000
3000
2000
1000
0
Zo
st
er
 in
ci
de
nc
e
(p
er
 1
,0
00
,0
00
 p
er
so
n-
ye
ar
s)
No MMRV Year 4 Year 15 Year 30 Year 80
Zoster cases optimal coverage
5000
4000
3000
2000
1000
0
Zo
st
er
 in
ci
de
nc
e
(p
er
 1
,0
00
,0
00
 p
er
so
n-
ye
ar
s)
No MMRV Year 4 Year 15 Year 30 Year 80
on. MMRV ¼ measles, mumps, rubella, and varicella.
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M.J.N.M. Ouwens et al.respectively. These results are comparable to those of
previous modelling studies in Canada,23 Finland,33
Australia,34 and the United States.35
Dynamic models generally require more data input
and assumptions than static models and can be
perceived as more complex or less transparent,
although the system is fully described with a limited
set of equations (as in Appendix A). The modeling
approach taken should reﬂect the nature of disease,
and as such, infectious diseases assessed through static
models do not consider the indirect effects at the
population level appropriately. In the past, the
uncertainty surrounding dynamic models was related
to the use of an assumption-based contact matrix. The
use of an empirical matrix in this model therefore
provides more transparency, robust data, and better
insight into the likely impact of routine vaccination at
the population level. In the empirical matrix, contacts
were not only deﬁned based on age but also on other
characteristics. For instance, Mossong et al27 assumed
that talking to or touching another person are the main
at-risk events for transmitting infectious diseases. This
assumption is well matched to the transmission mech-
anisms of varicella. The present estimates of varicella
incidence after vaccination are thus deemed more
reliable than past estimates. Since the recent publica-
tion of a contact matrix based on French sociodemo-
graphic data36 has become available, this has been
tested in our model and yields very similar results to
our empirically derived matrix from Italy.
There are a few published modeling studies that
have used an empirical matrix.33,37–39 However, the
distinguishing feature of this analysis is the application
of 2-dose vaccine efﬁcacy estimates from a recent
clinical trial.25 The model used the conservative
assumption that exogenous immunity boosting
existed, and as expected, this resulted in a temporary
increase in the number of zoster cases. The risks and
beneﬁts of vaccination need to be assessed in terms of
the impact on zoster epidemiology. The model
predicted an increase in zoster incidence; however,
this increase is expected to be modest and temporary.
Further research is needed to assess the exogenous
boosting theory, whether it exists, and how it
potentially affects the reactivation of VZV as zoster.
As more observational evidence is collected from
countries where routine varicella vaccination has been
maintained at high coverage for some years, it will be
important to monitor its effects on zoster in agingApril 2015vaccine recipients. Evidence from surveillance in the
United States from some regions show no increase in
zoster incidence, whereas another study in
Massachusetts did report an increase in zoster
incidence since implementing universal varicella
vaccination.35 In addition, analyses of zoster trends in
the United States show that zoster incidence was
already increasing in all age groups before varicella
vaccination.35,40 Published reports of varicella model–
based studies considering a prevaccination increase of
zoster or other potential factors affecting immunity
against zoster, such as endogenous boosting, are
limited.39 In a recently published report, a model
highlights the epidemiological differences between
European countries on the level of exogenous
boosting.39 As a consequence, introducing varicella
vaccination was predicted to have no increase in the
United Kingdom and a temporary increase in the
incidence of herpes zoster in Finland.39 It is known
that including such type of effects would further help
understand the impact of the varicella vaccination on
zoster epidemiology, and therefore future evaluations
to conﬁrm this theory are warranted.
CONCLUSIONS
This model provided a realistic representation of the
prevaccination situation in France. Implementation of
MMRV vaccination is expected to result in short-lived
indirect effects such as a transitory varicella peak in the
ﬁrst few years after vaccination and a modest tempo-
rary increase in the number of zoster cases. A limited
age shift was observed in the long term, given the
vaccination coverage assumptions. MMRV vaccination
is predicted to reduce the overall incidence of varicella
disease substantially.
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OVERVIEW OF MODEL PARAMETERS.
Table A1 and A2
APPENDIX B. CONTACT MATRIX
The following matrices were used in the base case and
scenario analyses. The contact matrix in the base case
was based on Italian contact data.27 For the assortative
and proportionate matrices, the structures were taken
from Brisson et al13 and adapted to who acquires
infection from whom (WAIFW) matrices using French
data for the force of infection.Table B1 and B2, B3
APPENDIX C. MODEL CALIBRATION AND
VALIDATION
Model Calibration
Contact Matrix
All people who have not yet had varicella are
susceptible or at risk of the disease. If a susceptible
person meets an infectious varicella patient, varicella
can be transmitted from the infectious person to the
susceptible person. For this, 3 things are important:
1) The proportion of the population that is infectious
2) The number of contacts within the population
3) Whether transmission takes place when there is
contact
When taking into account age groups, this translates
into:
1) The proportion of infectious individuals per age group
2) The number of contacts within the age group and
with other age groups
3) Whether transmission takes place when there is a
contact
Estimation of Force of Infection
Force of infection (FOI) for each age group is
computed based on the distribution of varicella cases
across age groups and the percentage of patients
having varicella in the total population.
The distribution of varicella cases across age groups
is based on the annual Sentiweb3 reports. The
percentage of the population that has previously had
varicella is also provided.
Let
 p1 be percentage of varicella cases that were in age
group 1 relative to all varicella cases;
 p2 be the percentage of the total population that has
varicella, and
 p3 be the percentage of the population that is in age
group 1;
 Then p1 * p2 is the percentage of the population
that both had varicella and were in age group 1.
Dividing by p3 results in the percentage of the age
group that has had varicella: p1 * p2/p3. Based on the
percentage having had varicella, the percentage suscep-
tible at the end of the age group can be computed. For
example, if 6.3% of individuals younger than 1 year
old had varicella, then 93.7% did not have it and are
still susceptible. Assuming an exponential distribution
within the age group, the rate needed to decrease from
the start percentage susceptible to the end percentage
susceptible is the FOI for the age group. For example, if
93.7% is susceptible at 1 year of age and 35.8% at 5
years of age, the FOI for 1 to 4 year olds is ln(35.8%/
93.7%)/(5  1) ¼ 0.24.
As such, the FOI can be obtained for all age groups.
The Sentiweb3 age groups were transformed to
match the model age groups. New age groups were
formed by averaging rates over the years of the new
age group. For example, for the age group 15 to 24
years, the rate is assumed to be equal to the average
rate of the rate for 15 to 19 years and the rate for 19 to
24 years.
Population Demographics
The birth percentage from INSEE31 is expressed in
terms of total population size. In addition to the birth
percentage, the mortality rates are provided. However,
applying the birth percentage and the mortality rates to
get the percentage of people of age 1 year, 2 years, etc,
does not imply that the percentages of all years
together add up to 1. Therefore, the birth rates and
mortality rates are used for age classes 0 years, 1 to 4
years, 5 to 9 years, 10 to 14 years, 15 to 24 years, 25 to
44 years, and 45 to 64 years. For 65þ years, the
assumption of a steady-state population was used (ie,
using the birth rate and mortality rates, the percentages
“within” the population add up to 100%).
Given the FOI and the mortality rates, the average
prevalence (expressed in percentage) of susceptible and
infectious cases is computed in each age group. These
are expressed in terms of total population by multi-
plying by age group size.
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Table A1. Model parameters.
Parameter Description Value Source
Demographic parameters
Birth Fraction of annual birth cohort of total French population 0.01295 INSEE, www.insee.fr31
Death All-cause mortality per year in France, by age group INSEE, www.insee.fr31
0
3.0355  103
1–4 y 3.01  104
5–9 y 1.04  104
10–14 y 1.0127  104
15–24 y 4.6679  104
25–44 y 1.06  103
45–64 y 5.12  103
65þ y 6.102  102
Biological parameters
σ Latent period of varicella
(average duration 14 days)
26.07 Brisson et al13
α Infectious period of varicella
(average duration 7 days)
52.14 Brisson et al13
δ Waning natural immunity
(average duration 10 years)
0.1 Expert opinion
g * λ (a) Exogenous boosting against zoster Brisson et al23
o50 y 75% * λ
50–64 y 71%* λ
465 y 50%* λ
α Infectious period of zoster
(average duration 7 days)
52.14 Brisson et al13
ρ (a) Reactivation rate of infectious zoster,
by age group
Calculated
0–4 y 0.028
5–9 y 0.009
10–14 y 0.0068
15–24 y 0.0035
25–44 y 0.0033
45–64 y 0.008
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Table A1. (continued).
Parameter Description Value Source
65þ y 0.016
ρ (a) without exogenous
boosting
Reactivation rate of infectious zoster, by age group Calculated
0 y 0.011134 17 y 0.003122 34 y 0.000944 51 y 0.004601
1 y 0.010501 18 y 0.002832 35 y 0.000998 52 y 0.004998
2 y 0.009889 19 y 0.002563 36 y 0.001072 53 y 0.005415
3 y 0.009296 20 y 0.002314 37 y 0.001166 54 y 0.005852
4 y 0.008724 21 y 0.002085 38 y 0.00128 55 y 0.006309
5 y 0.008172 22 y 0.001876 39 y 0.001414 56 y 0.006787
6 y 0.00764 23 y 0.001687 40 y 0.001569 57 y 0.007285
7 y 0.007128 24 y 0.001519 41 y 0.001743 58 y 0.007803
8 y 0.006637 25 y 0.00137 42 y 0.001938 59 y 0.008341
9 y 0.006166 26 y 0.001242 43 y 0.002153 60 y 0.008899
10 y 0.005714 27 y 0.001134 44 y 0.002389 61 y 0.009478
11 y 0.005284 28 y 0.001047 45 y 0.002644 62 y 0.010076
12 y 0.004873 29 y 0.000979 46 y 0.00292 63 y 0.010695
13 y 0.004482 30 y 0.000932 47 y 0.003216 64 y 0.011334
14 y 0.004112 31 y 0.000905 48 y 0.003532 65 y 0.011993
15 y 0.003762 32 y 0.000898 49 y 0.003868 —
16 y 0.003432 33 y 0.000911 50 y 0.004224 —
λ (a) Force of infection, by age group Based on INSERM26
0 y 0.0651
1–4 y 0.2407
5–9 y 0.2101
10–14 y 0.0672
15–24 y 0.0319
25–44 y 0.0288
45–64 y 0.0236
65þ y 0.0079
Vaccine parameters
MMR1 Coverage of ﬁrst dose of MMR, optimal scenario, % 95 Assumption based on
WHO2
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Table A1. (continued).
Parameter Description Value Source
MMR2 Coverage of second dose of MMR, optimal scenario, % 90 Assumption based on
WHO2
mmr1 Coverage of ﬁrst dose of MMR, French current coverage
scenario
90*
mmr2 Coverage of second dose of MMR, French current
coverage scenario, %
80
Dose 1 Age at ﬁrst vaccination (in months) 12 Assumption
Dose 2 Age at second vaccination, mo 18 Assumption
Replace No. of years before maximum replacement is reached 3 Assumption
Catch-up age Age at which catch-up program is provided (in years) 10 Assumption
Catch-up years No. of years in which catch-up program is provided 8 Assumption
Catch-up
coverage
Coverage in catch-up program, % 50 Assumption
Tv Varicella vaccine efﬁcacy (% successfully vaccinated and
temporarily protected)
65 Prymula et al25 (Phase
III trial,
NCT00226499)
P Varicella vaccine failures, % 5 Prymula et al25 (Phase
III trial,
NCT00226499)
1TvP Varicella vaccine recipients partially protected, % 30 100%-Tv-P
Wv1 Waning rate for 1 dose of varicella vaccine (duration 17 y) 0.0588 Silverman et al29
Wv2 Waning rate for 2 doses of varicella vaccine
(lifelong protection)
1e6 Expert opinion
Ki * λ (a) Rate of exogenous boosting 0.91 * λ (a) Brisson et al13
h Relative VZV reactivation after varicella vaccination 0.167 Brisson et al13
b * λ (a) Rate of infection among vaccinated susceptible individuals 0.73 * λ (a) Brisson et al13
m Rate of varicella infection in vaccine recipients vs
nonvaccine recipients
0.5 Brisson et al13
INSERM ¼ Institut national de la santé et de la recherche médicale; Ki ¼ proportion of contacts with infectious people leading to exogenous boosting; mmr ¼MMR ¼
measle, mumps, and rubella; P ¼ varicella vaccine failures; Tv ¼ varicella vaccine efﬁcacy.
*90% have only at least 1 dose.
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Table A2. Differential equations used in the model.
Continuous Flows Events (Once a Year) Relationship to Figure 1
dS(i,t)/dt ¼ S(i,t) * [λ(i,t) þ death(i)] þ Birth  aging  vaccination S
dSv(i,t)/dt ¼ Sv(i,t) * [λ(i,t) þ death(i)]  Aging  vaccination S
dE(i,t)/dt ¼ S(i,t) * λ(i,t) þ Sv(i,t) * λ(i,t)  E(i,t) * [σ þ death(i)]  Aging E
dInf(i,t)/dt ¼ E(i,t) * σ  Inf(i,t) * [α þ death(i)]  Aging I
dR(i,t)/dt ¼ Inf(i,t) * α  R(I,t) * δ þ Sz(i,t) * g * λ(i,t)  R(i,t) * death(i)  Aging R
dSz(i,t)/dt ¼ R(i,t) *δ  Sz(i,t) * g * λ(i,t)  Sz(i,t) * ρ(i)  Sz(i,t) * death(i)]  Aging Sz
dInfZ(i,t)/dt ¼ Sz(i,t) * ρ(i)  InfZ(i,t) * [α þ death(i)]  Aging Iz
dRz(i,t)/dt ¼ InfZ(i,t) * α  Rz(i,t) * death(i)  Aging Rz
dVP(i,t)/dt ¼ VP(i,t) * [WvþKi * λ(i,t) þ death(i)]  Aging  vaccination VP
dVPVP(i,t)/dt ¼ VPVP(i,t) * [Wv2 þ Ki * λ(i,t) þ death(i)]  Aging þ vaccination VP, double vaccination beneﬁt
dVS(i,t)/dt ¼ VP(i,t) * Wv þ VPVP(i,t) * Wv2  VS(i,t) * [b * λ(i,t) þ death(i)]  Aging  vaccination VS
dVE(i,t)/dt ¼ VS(i,t) * b * λ(i,t)  VE(i,t) * [σ þ death(i)]  Aging VE
dVInf(i,t)/dt ¼ VE(i,t) * σ  VInf(i,t) * [α þ death(i)]  Aging VI
dVR(i,t)/dt ¼ VInf(i,t) * α þ λ(i,t) * [VP(i,t) * Ki þ VPVP(i,t) * Ki þ VSz(i,t) * g] 
VR(i,t) * [δ þ death(i)]
 Aging VR
dVSz(i,t)/dt ¼ VR(i,t) * δ þ Wz * VZP(i,t)  VSz(i,t) * [g * λ(i,t) þ h * ρ(i) þ
death(i)]
 Aging vSz
dVInfZ(i,t)/dt ¼ VSz(i,t) * h * ρ(i)  VInfZ(i,t) * [α þ death(i)]  Aging VIz
dVRz(i,t)/dt ¼ VInfZ(I,t) * α  VRz(i,t) * [death(i)]  Aging VRz
 ¼ Vaccination refers to the fact that you can move in or out of compartments with the ﬁrst dose or second dose of measles, mumps, rubella, and varicella;
dt ¼ time derivative; t ¼ time; S ¼ susceptible; E ¼ latent or exposed; I ¼ infectious; R ¼ recovered; V ¼ vaccinated; Sz ¼ zoster susceptible; Iz ¼ zoster infectious;
Rz ¼ zoster recovered; all other acronyms are combinations of the above.
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Table B3. Proportionate matrix.
Age Group, y 0 1–4 5–9 10–14 15–24 25–44 45–64 65þ
0 85 317 277 88 41 37 30 9
1–4 317 1186 1035 327 153 138 112 34
5–9 277 1035 903 286 133 120 98 30
10–14 88 327 286 90 42 38 31 9
15–24 41 153 133 42 20 18 14 4
25–44 37 138 120 38 18 16 13 4
45–64 30 112 98 31 14 13 11 3
65þ 9 34 30 9 4 4 3 1
Table B1. Base case WAIFW matrix for France.
Age Group, y 0 1–4 5–9 10–14 15–24 25–44 45–64 65þ
0 107 398 98 21 19 46 35 21
1–4 398 1478 366 79 72 173 129 76
5–9 98 366 2166 351 55 163 143 74
10–14 21 79 351 3233 267 119 238 146
15–24 19 72 55 267 1337 213 205 72
25–44 46 173 163 119 213 314 190 102
45–64 35 129 143 238 205 190 230 130
65þ 21 76 74 146 72 102 130 144
Table B2. Assortative matrix.
Age Group, y 0 1–4 5–9 10–14 15–24 25–44 45–64 65þ
0 3688 28 28 28 28 28 28 28
1–4 28 1653 28 28 28 28 28 28
5–9 28 28 3544 28 28 28 28 28
10–14 28 28 28 6727 28 28 28 28
15–24 28 28 28 28 3986 28 28 28
25–44 28 28 28 28 28 3005 28 28
45–64 28 28 28 28 28 28 4664 28
65þ 28 28 28 28 28 28 28 28
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Standardization of Contact Matrix from Mossong et al23
The contact matrices from Mossong et al23 provide the number of contacts a person of a certain age group has
with people for each age group in a deﬁned time period. The columns show the age group of the participant. The
rows show the number of contacts. The probability of meeting someone with varicella is the sum over age groups
of the number of contacts with someone from the age group times the probability that the person met has
varicella. As such, the contact matrix needs to be multiplied by the proportion of varicella cases in each age group.
In the current paper, an Italian matrix was adapted for France. This means that the number of contacts was based
on the size of the age groups in Italy, whereas the percentage of varicella cases per age group was based on French
data. The population effect was taken out by expressing the prevalence in terms of total population and thus
dividing the Italian contact matrix23 rows by relative age group size in Italy. Note that when the matrix would be
based on the same population, thus dividing and multiplying would cancel itself out.
Because the number of contacts of the age group A with age group B is equal to the number of contacts of age
group B with age group A, and the contact matrix after division is not dependent on the size of the age groups
anymore, the resulting matrix should be symmetrical. This is used to improve the matrix by taking the average of
the transpose and the matrix itself. The Italian contact matrix23 did not use the same age categories that were
needed for this analysis. We expressed the contact matrix from Mossong et al23 using age groups of the model by
taking weighted averages. In more detail, the 0-year age group came from the 0 to 4 years age group of Mossong
et al23 as did 1 to 4 years, 5 to 9 years, and 10 to 14 years age groups. Data for the 15 to 24 years age group were
obtained from 15 to 19 and 20 to 24 years age groups. As such, we averaged the values for 15 to 19 and 20 to 24
years age groups. Likewise, the values for 25 to 44, 45 to 64, and 65þ years age groups were obtained by
weighted averages.
FOI and Contact Matrix
Approximation 1
The FOI is modeled as the importation factor (assumed) plus the product of the transmission rate q, the
standardized contact matrix (β), and the sum of the vector of prevalent varicella cases (V), expressed in terms of
total population, and the vector of prevalent zoster cases (Z) multiplied by 1%.
FOItotal ¼ q  β  (V þ 0.01  Z) þ Importation
Only q is unknown. This parameter is estimated assuming independence of the conditional percentage
reduction within the different age groups, using a multinomial distribution.
Approximation 2
For this approximation, the number of contacts of 0 years of age with the environment is assumed to be
different from the number of contacts for 1 to 4 years. This is performed by assuming that the number in the 0 to
4 years age group is a result of a weighted average of number of contacts of 0 years of age and of 1 to 4 years of
age. This is done by left and right multiplication of the standardized matrix with a diagonal matrix with ones on
the entries not corresponding to the age group 0 years/1 to 4 years and with (1  Ω) at the diagonal entry for 0
years and (1 þ age group size 0 years/age group size 1–4 years) as diagonal element for 1 to 4 years.
Similarly to approximation 1, the FOI is modeled as the immigration factor plus the product of the
transmission rate q, the standardized contact matrix, and the sum of the vector of prevalent varicella cases,
expressed in terms of total population, and the vector of prevalent zoster cases multiplied by 1%.
q and Ω were unknown. These parameters were estimated assuming independence of the conditional
percentage reduction within the different age groups using a multinomial distribution.
Approximation 3
Instead of using a limited number of parameters, the matrix is obtained using left and right multiplication with
a diagonal matrix, where all diagonal elements were unknowns. The diagonal elements were computed so that a
perfect ﬁt was obtained.
Clinical Therapeutics
829.e7 Volume 37 Number 4
Instead of evaluating the uncertainty in the parameters, the estimated and data-driven FOIs were plotted to
assess whether the result was sufﬁciently good.
A comparison of the percentage of people having had varicella in each age group of the model with observed
data from France are shown: Approximation 1 (Figure C1), Approximation 2 (Figure C2), and Approximation 3
(Table C1).
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Figure C1. Approximation 1: Percentage Estimated Versus Percentage Fitted.
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Figure C2. Approximation 2: Percentage Estimated Versus Percentage Fitted.
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Model Validation
The results of the model validation are provided in Table C2.
Table C1. Approximation 3: percentage estimated
versus percentage fitted.
Calculated Based
on Beta Matrix31 þImportation* Difference
0.06408065 0.06508065 4.57515E-09
0.23974335 0.24074335 4.80506E-09
0.20911805 0.21011805 8.25672E-10
0.0661619 0.0671619 2.02482E-09
0.03089866 0.03189866 4.91945E-09
0.02784409 0.02884409 2.20658E-10
0.02260891 0.02360891 3.91594E-09
0.00690335 0.00790335 4.89891E-09
The second approximation was selected because it
reproduced the data sufﬁciently accurately without
increasing the number of parameters that could
potentially be overﬁtted.
*Fixed number of varicella cases coming from outside the
country.
Table C2. Varicella and zoster incidence, Sentiweb data, and model distribution.
Age Group, y
Varicella Zoster
Sentiweb 20063 Model Distribution Sentiweb 20063 Model Distribution
0 to o1 6% 6% 2%* —
1–4 59% 59% 2%
5–9 23% 21% 3% 3%
10–14 4% 5% 4% 4%
15–24 3% 3% 6% 6%
25–44 3% 4% 14% 13%
45–64 1% 2% 32% 31%
65þ 0% 0% 41% 41%
Total 100% 100% 100% 100%
Incidence (per million population) 12,200 12,707 4017 4045
*Includes 0 to 4 years age group.
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